Deletions in guaBA and htrA but not clpX or rfaL constitute a live-attenuated vaccine strain of Salmonella Newport to protect against serogroup C2-C3 Salmonella in mice

@article{Fuche2018DeletionsIG,
  title={Deletions in guaBA and htrA but not clpX or rfaL constitute a live-attenuated vaccine strain of Salmonella Newport to protect against serogroup C2-C3 Salmonella in mice},
  author={Fabien J. Fuche and Jennifer A. Jones and Girish Ramachandran and Ellen E. Higginson and Raphael Simon and Sharon M. Tennant},
  journal={Human Vaccines \& Immunotherapeutics},
  year={2018},
  volume={15},
  pages={1427 - 1435},
  url={https://api.semanticscholar.org/CorpusID:49330840}
}
A Salmonella Newport-based live-attenuated vaccine (serogroup C2-C3) elicited strong antibody responses against COPS, flagellin and outer membrane proteins when administered intraperitoneally or orally and significantly reduced the bacterial burden of challenge organisms in the liver and spleen following lethal challenge.
View on Taylor & Francis
tandfonline.com
10 Citations
Background Citations
4
Methods Citations
2

10 Citations

Refinement of a Live Attenuated Salmonella enterica Serovar Newport Vaccine with Improved Safety

The data demonstrate that this work has constructed a well-tolerated, effective live attenuated S. Newport vaccine which elicits functional antibodies against serogroup O:8 but not O:6,7 serovars.

Advances in the development of Salmonella‐based vaccine strategies for protection against Salmonellosis in humans

Recent advances have led to the development of new vaccines against Salmonella which have or will soon be tested in clinical trials, and adaptation of attenuated strains as sources of purified antigens and vesicles that can be used for subunit and conjugate vaccines or together with attenuated vaccine strains in heterologous prime‐boosting immunization strategies.

Genetic engineering of Salmonella spp. for novel vaccine strategies and therapeutics

Current progress of recombinant live-attenuated Salmonella vaccines, their use as a source of antigens for parenteral vaccines, their use as live-vector vaccines to deliver foreign antigens, and their use as therapeutic cancer vaccines in humans are focused on.

The impact of sseK2 deletion on Salmonella enterica serovar typhimurium virulence in vivo and in vitro

It is concluded that sseK2 is a virulence-associated gene that plays a vital role in Salmonella virulence and vaccinating mice with the ΔsSEK2 mutant protected them against challenge with a lethal dose of the WT strain.

The Evolution of Vaccines Development across Salmonella Serovars among Animal Hosts: A Systematic Review

The most efficacious vaccine antigen candidate found was recombinant heat shock protein with an incomplete Freund’s adjuvant evaluated in a murine model, and the highest efficacy vaccine candidates demonstrated were bacterial ghost vaccine candidates.

Immunogenicity and Induction of Functional Antibodies in Rabbits Immunized with a Trivalent Typhoid-Invasive Nontyphoidal Salmonella Glycoconjugate Formulation

The immunogenicity of multivalent formulations of iNTS COPS:FliC conjugates with Typbar-TCV™ is reported, and rabbit sera mediated bactericidal activity in-vitro, and protected mice after passive transfer against challenge with virulent SE or STm Malian blood isolates support accelerated progression to clinical trials.

The CRISPR genotypes and genetic diversity of different serogroups of nontyphoidal Salmonella in Guizhou Province, 2013–2018

The CRISPR genotyping was an effective typing method that could reveal the genetic diversity of different nontyphoidal Salmonella serotypes except for S. Enteritidis.

A broadly immunogenic polyvalent Shigella multiepitope fusion antigen protein protects against Shigella sonnei and Shigella flexneri lethal pulmonary challenges in mice

Results indicated that this Shigella MEFA protein is broadly immunogenic, induces broadly functional antibodies, and cross-protects against lethal pulmonary challenges with S. sonnei or S. flexneri serotype 2a, 3a, or 6, suggesting a potential application of this polyvalent MEFAprotein in Shiglla vaccine development.

Intracellular Survival and Pathogenicity Modulation of Salmonella Lon, CpxR, and RfaL Mutants Used as Live Bacterial Vectors under Abiotic Stress, Unveiling the Link between Stress Response and Virulence in Epithelial Cells

Analysis of two Salmonella Typhimurium strains engineered from the wild-type JOL 401 strain through in-frame deletions of the lon and cpxR genes provides valuable insights into the mechanisms governing the association, internalization, and survival of Salmonella mutants, enhancing the understanding of their regulatory effects on host cell physiology.

Vaccines for enteric diseases

Rotavirus was the leading cause of diarrheal diseases deaths, being responsible for 228,000 deaths in all age groups, followed by Shigella causing 212,000 Deaths, and enterotoxigenic Escherichia coli (ETEC) causing 51,000Deaths.

49 References

Utilization of a novel autologous killed tri-vaccine (serogroups B [Typhimurium], C [Mbandaka] and E [Orion]) for Salmonella control in commercial poultry breeders

The success of this trial resulted in the incorporation of this vaccine into a Salmonella control system in commercial broiler breeder production.

Cell-Associated Flagella Enhance the Protection Conferred by Mucosally-Administered Attenuated Salmonella Paratyphi A Vaccines

It is speculated that an excess of IgG1 anti-FliC antibodies induced by the exported FliC may compete with the IgG2a subtype and block binding to specific phagocyte Fc receptors that are critical for clearing an S. Paratyphi A infection.

Engineering and Preclinical Evaluation of Attenuated Nontyphoidal Salmonella Strains Serving as Live Oral Vaccines and as Reagent Strains

These findings can pave the way for development of a highly effective, broad-spectrum vaccine against invasive NTS, as S. Typhimurium and S. Enteritidis are the most common NTS serovars associated with invasive disease.

Salmonella Serogroup C: Current Status of Vaccines and Why They Are Needed

The underestimated burden represented by serogroup C NTS is described, as well as a discussion of vaccines that target these pathogens.

Characterization of Candidate Live Oral Salmonella typhi Vaccine Strains Harboring Defined Mutations inaroA, aroC, and htrA

Loss of the HtrA protease in S. typhi does not seem to alter its ability to invade epithelial cells or macrophages or to induce proinflammatory cytokines such as IL-8 but significantly reduces intracellular survival in human intestinal epithelial Cells in vitro and in vivo.

Development of a glycoconjugate vaccine to prevent invasive Salmonella Typhimurium infections in sub-Saharan Africa

Development of a STm glycoconjugate vaccine comprised of STm COPS conjugated to the homologous serovar phase 1 flagellin protein (FliC) with assessment of the role of COPS O-acetyls for functional immunity is reported.

Salmonella enterica Serovar Enteritidis Core O Polysaccharide Conjugated to H:g,m Flagellin as a Candidate Vaccine for Protection against Invasive Infection with S. Enteritidis

Mice immunized with flagellin alone, COPS-CRM197, or COPs-flageLLin conjugates were significantly protected from lethal challenge with wild-type S. Enteritidis cells into mouse macrophages.

Hyperinvasiveness of Salmonella enterica serovar Choleraesuis linked to hyperexpression of type III secretion systems in vitro

S. Choleraesuis showed hyperinvasiveness in cellular as well as mouse models due to hyperexpression of T3SS genes, and was found to be more invasive to humans than S. Typhimurium.

Two Novel Salmonella Bivalent Vaccines Confer Dual Protection against Two Salmonella Serovars in Mice

Two novel Salmonella bivalent vaccines are developed, SLT26 (pCZ11) and SLT27 (pZ11), suggesting that the delivery of a heterologous O-antigen in attenuatedSalmonella strains is a prospective approach for developing Salmoneella vaccines with broad serovar coverage.

Comparative analysis of Salmonella enterica serovar Enteritidis mutants with a vaccine potential.